(R)-Fadrozole

(R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor[1]. (R)-Fadrozole also inhibits human placental aromatase (pIC50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats.[1][2].

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Others >> Others

pIC50: 6.17 (human placental aromatase)

The (-)-enantiomer with the S-absolute configuration was responsible for the high aromatase inhibitory activity of (R)-Fadrozole[1].

(R)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) and (S)-fadrozole similarly decreases plasma aldosterone levels, whereas urinary aldosterone excretion rate was reduced only by S-fadrozole[2]. (R)-fadrozole (0.24 and 1.2 mg/kg; daily; oral) effectively reverses preexistent left ventricular interstitial fibrosis by 50% (vs. 42% for canrenoate), S-fadrozole was devoid of an antifibrotic effect[2]. Animal Model: SHHF rats[2] Dosage: 0.24 and 1.2 mg/kg Administration: Daily; oral Result: Decreased plasma aldosterone levels and reversed preexistent left ventricular interstitial fibrosis.

[1]. Furet P, et al. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem. 1993;36(10):1393-1400.

[2]. Minnaard-Huiban M, et al. Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats: discordant enantioselectivity versus reduction of plasma aldosterone. Endocrinology. 2008;149(1):28-31.